KR20200092069A - Apparatus for oscillate jet injecting lipolysis composition - Google Patents

Abstract

The present invention relates to an apparatus for injecting a lipolytic composition. The apparatus for injecting a lipolytic composition according to an embodiment of the present invention includes: a lipolytic composition storage unit; a pump; and one or more nozzle-type needles.

Description

Vibration injection device for lipolysis composition {APPARATUS FOR OSCILLATE JET INJECTING LIPOLYSIS COMPOSITION}

The present invention relates to a device for vibration injection of lipolysis composition.

As the body contouring market demand is huge and continues to grow every year, various methods of liposuction and lipolysis are being developed.

In view of the shortcomings faced by liposuction in the past, manufacturers in the field of weight control and body contouring have developed their main interest in methods of minimally invasive and even noninvasive lipolysis in traditional liposuction. However, even if an anesthetic is added to the injection solution, after the anesthesia has subsided, there are still side effects such as severe inflammation and pain at the injection site, and in severe cases, there is a risk of postoperative pain, nerve paralysis, local tissue necrosis or infection, etc. It may be limited in.

Accordingly, it is the market to develop a topical lipolysis injection device capable of overcoming the above-mentioned disadvantages and limitations, effectively maximizing local fat, having reduced side effects, and meeting consumer's high demand for safer products. Is the trend.

The present invention is to solve the above-mentioned problems, the object of the present invention is to minimize the side effects of the depression, skin sagging and wrinkles of the skin due to the pain of the patient due to pain, difficult to remove a wide range of fat, It is to provide an apparatus for injecting a lipolysis composition capable of evenly removing a wide range of fats and minimizing side effects of skin dent, sagging, or wrinkles.

However, the problems to be solved by the present invention are not limited to those mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.

According to an embodiment of the present invention, the lipolysis composition storage unit; Pump; And one or more nozzle-type needles.

According to one embodiment, the pump may be to periodically supply the lipolysis composition to the nozzle needle.

According to one embodiment, the lipolysis composition may be a high pressure injection to the subcutaneous fat layer through the nozzle-type needle.

According to one embodiment, the lipolysis composition may be a periodic high pressure injection to the subcutaneous fat layer through the nozzle-type needle by the periodic supply of the pump.

According to one embodiment, through the periodic high-pressure injection, it may be to impart vibration to the subcutaneous fat layer.

According to one embodiment, the vibration may be a repetitive vibration of 10 Hz to 1000 Hz.

According to one embodiment, the high pressure injection may be performed at a pressure of 50 psi to 1000 psi.

According to one embodiment, the lipolysis composition is 300 ml/min. To 1000 ml/min. It may be supplied.

According to one embodiment, it may be to include 4 to 8 of the nozzle-type needle.

According to an embodiment, the nozzle-type needle may be inserted into the subcutaneous fat layer at 10 cm to 20 cm intervals.

According to an embodiment, the nozzle-type needle may include a horizontal injection port at the end of the nozzle-type needle portion.

According to one embodiment, the longitudinal end of the nozzle-type needle may be blocked.

According to one embodiment, the injection of the lipolysis composition through a horizontal injection hole of the nozzle-type needle may include a radial spray type injection.

According to one embodiment, the nozzle-type needle is 4 or more, and is formed at intervals of 10 cm to 20 cm through the flexible patch-type plate, and the length of the needle passing through the flexible patch-type plate ranges from 1 cm to 5 cm. It may be adjustable.

According to the lipolysis composition injection device of the present invention, the lipolysis composition can be effectively injected between the skin layer and the subcutaneous layer, the impact or irritation of the subcutaneous fat can be minimized, and the lipolysis efficiency can be maximized. In addition, it is possible to perform a stable and efficient lipolysis procedure along with an accurate procedure. And, while minimizing side effects such as pain, bruising, erythema, swelling, swelling, itching, or side effects of skin depression, skin sagging and wrinkles due to the patient's feeling of rejection due to pain, and difficulty in removing a wide range of fat. , It can maximize the effect of lipolysis at the local site.

1 is a system configuration diagram of a lipolysis composition injection device according to an embodiment of the present invention.
2 is a view showing a nozzle-type needle according to an embodiment of the present invention.
3 is a view showing a nozzle-type needle according to another embodiment of the present invention.
Figure 4 is a view showing the injection of the lipolysis composition through a horizontal injection nozzle of the nozzle-type needle according to an embodiment of the present invention.
5 is a view showing a nozzle-type needle through a flexible patch-type plate according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings. In describing the present invention, when it is determined that a detailed description of related known functions or configurations may unnecessarily obscure the subject matter of the present invention, the detailed description will be omitted. In addition, terms used in the present specification are terms used to appropriately represent a preferred embodiment of the present invention, which may vary depending on a user, an operator's intention, or a custom in the field to which the present invention pertains. Therefore, definitions of these terms should be made based on the contents throughout the present specification. The same reference numerals in each drawing denote the same members.

Throughout the specification, when one member is positioned "on" another member, this includes not only the case where one member is in contact with the other member but also another member between the two members.

Throughout the specification, when a part “includes” a certain component, it means that the other component may be further included instead of excluding the other component.

The present invention, as a result of clinical trials to minimize effective lipolysis and side effects, completed the present invention by identifying the optimal active ingredient and the composition components of the additive.

Hereinafter, the lipolysis composition injection device of the present invention will be described in detail with reference to examples and drawings. However, the present invention is not limited to these examples and drawings.

According to an embodiment of the present invention, the lipolysis composition storage unit; Pump; And one or more nozzle-type needles.

1 is a system configuration diagram of a lipolysis composition injection device according to an embodiment of the present invention. Referring to Figure 1, the lipolysis composition injection device 100 according to an embodiment of the present invention, the lipolysis composition storage unit 110, a pump 120, a nozzle-type needle 130 and the control unit 140 Includes.

According to an embodiment, the lipolysis composition storage unit 110 may include a lipolysis composition or a lipolysis gas.

According to one embodiment, the lipolysis composition, bimatoprost, prostaglandin, latanoprost, travoprost, statin, hyaluronidase, resveratrol, deoxycholic acid, ritolinic acid, isoproterenol and pen At least one fat-decomposing compound selected from the group consisting of toxicoline; At least one lipolysis promoter selected from the group consisting of L-carnitine, carnitine and levocarnitine chloride; At least one collagen production accelerator selected from the group consisting of vitamin C, glycosaminoglycan and alginic acid; At least one antihistamine selected from the group consisting of olopatadine, azelastine and pheniramine; At least one local anesthetic selected from the group consisting of procaine, chloroprocaine, tetracaine, prilocaine, lidocaine, mepivacaine, bupivacaine, ropivacaine, etidocaine, lidocaine hydrochloride, benzocaine and oxetazine ; And a pharmaceutically acceptable carrier.

According to one embodiment, the fat-decomposing compound may use a fat-decomposing compound, but preferably, bimatoprost, prostaglandin, latanoprost, travoprost, statin, hyaluronidase, resveratrol, deoxycholic acid , Litocholinic acid, isoproterenol and pentoxifylline.

According to one embodiment, the lipolysis accelerator may use an accelerator for decomposing fat, but may be, for example, at least one selected from the group consisting of L-carnitine, carnitine and levocarnitine chloride.

According to one embodiment, the collagen production accelerator may use an accelerator that produces collagen, but may preferably be at least one selected from the group consisting of vitamin C, glycosaminoglycan, and alginic acid.

According to one embodiment, the antihistamine is an agent that antagonizes the action of histamine. In general, an agent used for the purpose of preventing or alleviating allergic symptoms may be used, but preferably olopatadine, azelastine and penirr It may be at least one selected from the group consisting of amines.

According to one embodiment, the local anesthetic is used for the purpose of alleviating pain when injecting the injectable composition, which may generally use a formulation used for the purpose of local anesthesia, but preferably procaine, chloropro Caine, tetracaine, prilocaine, lidocaine, mepivacaine, bupivacaine, ropivacaine, etidocaine, lidocaine hydrochloride, benzocaine, and at least one selected from the group consisting of oxetazine.

According to one embodiment, the pharmaceutically acceptable carrier may use oils, non-aqueous carriers, diluents, solvents, vehicles used in compositions for parenteral administration, ie injection or bolus injection. Examples of oils or non-aqueous carriers, diluents, solvents or vehicles, include or mold propylene glycol, polyethylene glycol, vegetable oils (e.g. olive oil) and injectable organic esters (e.g. ethyl oleate) Formulations such as preservatives, wetting agents, emulsifying or suspending agents, stabilizers and/or dispersing agents. The lipolysis composition is preferably an injectable formulation, and in one aspect, the composition may be an injectable formulation to be mixed with physiological saline for injection just prior to use, or a liquid formulation dissolved in injectable water.

According to one embodiment, the lipolysis composition may be administered, for example, in the forearm, abdomen, thighs, face, buttocks, for topical fat removal. More specifically, the lipolysis composition may also be used in a method of removing local fat through the lymphatic vessel (Lipolytic Lymph Drainage, LLD treatment) by subcutaneous injection or the like to a site having a large amount of local fat and then massaging the injection site.

According to one embodiment, the lipolysis composition, the lipolysis compound 10 to 15% (v / v); Lipolysis accelerator 5 to 10% (v/v); Collagen production accelerator 2.5-3.0% (v/v); Antihistamines 0.03 to 0.04% (v/v); And 0.5 to 0.6% (v/v) of local anesthetic. In the composition, the blending ratio of components contained by a person skilled in the art may vary depending on the weight, sex, or clinical condition of the administration target.

According to one embodiment, when the fat-decomposing compound contains less than 10% (v/v), the fat-decomposing effect is not sufficient, and when it contains more than 15% (v/v), it is difficult to remove a wide range of fat evenly. As a result, side effects such as depression of the skin, sagging of the skin, and wrinkles occur. Considering the appropriate ratio of the fat-decomposing compound, if the fat-decomposition promoting agent contains less than 5% (v/v), the fat-decomposing effect is insufficient, and if it exceeds 10% (v/v), the fat-decomposing effect Causes excessive side effects. When the collagen production accelerator is included in an amount of less than 2.5% (v/v), the effect of promoting collagen production is insufficient, and when it is included in an amount exceeding 3.0% (v/v), a side effect of excessive collagen production occurs. If the antihistamine agent is included in an amount of less than 0.03% (v/v), the effect of preventing allergies is insufficient, and when it is included in an amount exceeding 0.04% (v/v), an adverse effect caused by the antihistamine agent occurs. In addition, the effect of anesthesia containing less than 0.5% (v/v) of the local anesthetic is not sufficient, and when it exceeds 0.6% (v/v), the time for anesthesia is released is prolonged, resulting in discomfort in daily life after the procedure. .

According to one embodiment, the hyaluronidase in the lipolysis compound may use the most effective unit for lipolysis, but preferably 600 IU to 900 IU. If the hyaluronidase unit contains less than 600 IU, not only the fat decomposition effect is not sufficient, but also the injection interval needs to be injected narrowly, the number of injections increases, and if it contains more than 900 IU, fat The decomposition of the skin becomes bumpy due to excessive decomposition. In addition, in the above unit range, when the injection solution was injected at a dose of 1 cc in units of 600 IU, it was confirmed that the diffusion range of the active ingredient was 1 to 2.5 cm. Therefore, the injection interval is injected from 1 cm to 2.5 cm to provide an effect of reducing the number of injections and evenly dissolving fat.

According to one embodiment, the lipolysis gas includes at least one gas of carbon dioxide, oxygen, and hydrogen. Of course, in addition, any gas can be included as long as it can be used for lipolysis.

The lipolysis composition injection device of the present invention may be one that sequentially injects a lipolysis gas and a lipolysis composition into the skin. By initially introducing a lipolysis gas into the skin layer, separating the layers, and adopting a procedure method of injecting a lipolysis composition in a state where space is secured, the drug can be effectively injected between the skin layer and the subcutaneous layer, and thus, with the correct procedure, Stable and efficient lipolysis procedure can be performed.

According to one embodiment, the lipolysis composition storage unit 110 may include a plurality of lipolysis composition storage units 110 that respectively store the lipolysis composition or the lipolysis gas.

According to one embodiment, the pump 120 may be to periodically supply the lipolysis composition to the nozzle-type needle 130.

According to one embodiment, the nozzle-type needle 130 is a lipolysis composition or fat fraction stored in the lipolysis composition storage unit 110 in the area of the surgical site, for example, thigh, calf, buttocks, face, etc. It is provided to be able to inject gas.

According to one embodiment, the control unit 140 may be to control the injection volume, the number of injections, the injection time and injection depth, etc. according to the injection site of the lipolysis composition.

According to one embodiment, the lipolysis composition may be a high pressure injection to the subcutaneous fat layer through the nozzle-type needle 130.

According to one embodiment, the lipolysis composition may be a periodic high pressure injection to the subcutaneous fat layer through the nozzle-type needle by the periodic supply of the pump. Impact or irritation to the subcutaneous fat may be minimized by the periodic supply of the lipolysis composition.

According to one embodiment, through the periodic high-pressure injection, it may be to impart vibration to the subcutaneous fat layer. The oscillation can maximize the efficiency of lipolysis in the subcutaneous fat because periodic high-pressure injection becomes continuous.

According to one embodiment, the vibration may be a repetitive vibration of 10 Hz to 1000 Hz. Vibration in the above range makes it possible to achieve an appropriate compromise between the lipolysis composition delivery range and the transmittance to the subcutaneous fat layer.

According to one embodiment, the high pressure injection may be performed at a pressure of 50 psi to 1000 psi. If the injection is less than 50 psi, there may be a problem that fat decomposition by high pressure injection may not occur, and if it exceeds 1000 psi, there may be a problem that causes excessive shock or irritation to the periphery.

According to one embodiment, the lipolysis composition is 300 ml/min. To 1000 ml/min. It may be supplied. Since the lipolysis composition is administered together with vibration at a dose in the above range, non-invasive complex decomposition of fat is performed, and thus there is an effect of increasing the removal efficiency and fat decomposition efficiency of fat accumulation sites in the body.

According to one embodiment, it may be to include 4 to 8 of the nozzle-type needle 130. Simultaneous administration with at least 4 injection points provides the effect of reducing the treatment time.

According to an embodiment, the nozzle-type needle 130 may be inserted into the subcutaneous fat layer at 10 cm to 20 cm intervals. When the nozzle-type needle point interval is injected less than 10 cm, the number of injections increases, and the active ingredient of the composition overlaps the skin, resulting in a phenomenon in which fat decomposition is excessive in a part of the skin, and the skin is bumpy at a dense interval. As the phenomenon occurs, and when the injection point interval exceeds 20 cm, the active ingredient does not work evenly and it is difficult to remove a wide range of fat evenly.

According to one embodiment, the lipolysis composition may be administered to a depth that optimally indicates the effect of lipolysis depending on the administration site of the subject, but may preferably be administered to a depth of 4 mm to 6 mm from the skin surface layer. have.

2 is a view showing a nozzle-type needle according to an embodiment of the present invention. Referring to FIG. 2, the nozzle-type needle 130 according to an embodiment of the present invention may include a horizontal injection hole 132 and a central injection hole 134 at the end of the nozzle-type needle.

3 is a view showing a nozzle-type needle according to another embodiment of the present invention. Referring to FIG. 3, the longitudinal end 136 of the nozzle-type needle 130 according to another embodiment of the present invention may be blocked.

Figure 4 is a view showing the injection of the lipolysis composition through a horizontal injection nozzle of the nozzle-type needle according to an embodiment of the present invention. Referring to FIG. 4, injection of the lipolysis composition through a horizontal injection hole of the nozzle-type needle 130 may include radial spray-type injection.

5 is a view showing a nozzle-type needle through a flexible patch-type plate according to an embodiment of the present invention. Referring to FIG. 5, the nozzle-type needle 130 may be formed through the flexible patch-type plate 150.

According to one embodiment, the nozzle-type needle is 4 or more, and is formed at intervals of 10 cm to 20 cm through the flexible patch-type plate, and the length of the needle passing through the flexible patch-type plate ranges from 1 cm to 5 cm. It may be adjustable. The needle penetrating the flexible patch-type plate may be attached to the lipolysis target site in the form of a patch and delivered to the target site. By using such a patch form, it can be simultaneously administered to a plurality of injection points at regular intervals, thereby reducing the treatment time.

Hereinafter, the present invention will be described in more detail by examples and comparative examples.

However, the following examples are only for illustrating the present invention, and the contents of the present invention are not limited to the following examples.

[Example]

1. Preparation and procedure of lipolysis composition

A lipolysis composition for injection was prepared as shown in Table 1 below.

ingredient Lipolysis compounds Lipolysis
accelerant Collagen
Production accelerator Antihistamine Topical
anesthetic carrier Example 1 Hyaluronidase
700IU Carnitine
10% (v/v) Vitamin C
3.0% (v/v) Pheniramine
0.04% (v/v) Lidocaine
0.6% (v/v) Physiology
Saline
Remainder Example 2 Resveratrol
15% (v/v) Example 3 Statin
15% (v/v)

Recall hyaluronidase (Daehan New Farm), carnitine (Midme Co., Ltd.), vitamin C (Daum Co., Ltd.), pheniramine (Yuhan Corporation), lidocaine (Daehan Pharmaceutical Industry), resveratrol (Solgar), statin (United Interfarm) By mixing in content, a lipolysis composition for injection was prepared.

2. Fat decomposition effect of lipolysis composition

The lipolysis composition of Examples 1 to 3 was put in the lipolysis composition storage unit of the lipolysis composition injection device of the present invention, and a procedure was performed to investigate the lipolysis effect. Ten patients with abdominal obesity with a BMI of 25 or more among the adult men and women over 20 years of age were administered to the abdomen at intervals of 2 cm. The average of the results is shown in Table 2 below.

Composition Difference in waist circumference after administration Difference in waist circumference after 1 month Skin depression phenomenon Example 1 -5.6±0.4 -0.6±0.4 X Example 2 -4.3±0.2 +0.2±0.1 X Example 3 -4.0±0.3 +0.4±0.2 X

For statistical analysis and verification method, SPSS statistical package was used to obtain the distribution of measurements, paired t-test was used to see the abdominal waist circumference reduction effect by experimental injection, and the verification interval for reliability was determined within 95%. When the lipolysis composition of Examples 1 to 3 was put in the lipolysis composition storage unit of the lipolysis composition injection device of the present invention and the lipolysis effect was observed, a significant waist circumference reduction effect was exhibited, and skin deterioration did not occur. It was confirmed that no yo-yo occurred after 1 month.

As described above, although the embodiments have been described by the limited embodiments and drawings, those skilled in the art can make various modifications and variations from the above description. For example, even if the described techniques are performed in a different order than the described method, and/or the described components are combined or combined in a different form from the described method, or replaced or replaced by another component or equivalent Appropriate results can be achieved. Therefore, other implementations, other embodiments, and equivalents to the claims are also within the scope of the following claims.

100: lipolysis composition injection device
110: lipolysis composition storage unit
120: pump
130: nozzle type needle
132: horizontal nozzle
134: Central injection hole
136: end
140: control unit
150: flexible patch type plate

Claims (14)

Lipolysis composition storage;
Pump; And
One or more nozzle type needles;
Lipolysis composition injection device comprising a.
According to claim 1,
The pump,
It is to periodically supply the lipolysis composition to the nozzle-type needle,
Lipolysis composition injection device.
According to claim 1,
The lipolysis composition is a high-pressure injection to the subcutaneous fat layer through the nozzle-type needle,
Lipolysis composition injection device.
According to claim 1,
The lipolysis composition is periodically high-pressure injection to the subcutaneous fat layer through the nozzle-type needle by the periodic supply of the pump,
Lipolysis composition injection device.
According to claim 4,
Through the periodic high-pressure injection, to impart vibration to the subcutaneous fat layer,
Lipolysis composition injection device.
The method of claim 5,
The vibration is a repeated vibration of 10 Hz to 1000 Hz,
Lipolysis composition injection device.
According to claim 4,
The high pressure injection is carried out at a pressure of 50 psi to 1000 psi,
Lipolysis composition injection device.
According to claim 4,
The lipolysis composition was 300 ml/min. To 1000 ml/min. To be supplied,
Lipolysis composition injection device.
According to claim 1,
Which includes 4 to 8 of the nozzle needles,
Lipolysis composition injection device.
The method of claim 7,
The nozzle-type needle is inserted into the subcutaneous fat layer is located at intervals of 10 cm to 20 cm,
Lipolysis composition injection device.
According to claim 1,
The nozzle-type needle, which includes a horizontal injection port at the end of the nozzle-type needle portion,
Lipolysis composition injection device.
The method of claim 11,
The longitudinal end of the nozzle-type needle is blocked,
Lipolysis composition injection device.
The method of claim 12,
The injection of the lipolysis composition through the horizontal injection hole of the nozzle-type needle includes a radial spray type injection,
Lipolysis composition injection device.
According to claim 1,
The nozzle-type needle is four or more, is formed at intervals of 10 cm to 20 cm through the flexible patch-type plate, the length of the needle through the flexible patch-type plate is adjustable in the range of 1 cm to 5 cm,
Lipolysis composition injection device.

Images